Altimmune, Inc. (ALT): Price and Financial Metrics


Altimmune, Inc. (ALT): $20.03

-0.21 (-1.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALT POWR Grades

  • Growth is the dimension where ALT ranks best; there it ranks ahead of 71.94% of US stocks.
  • The strongest trend for ALT is in Growth, which has been heading up over the past 179 days.
  • ALT's current lowest rank is in the Stability metric (where it is better than 2.66% of US stocks).

ALT Stock Summary

  • For ALT, its debt to operating expenses ratio is greater than that reported by just 0.49% of US equities we're observing.
  • ALT's price/sales ratio is 294.96; that's higher than the P/S ratio of 98.77% of US stocks.
  • Revenue growth over the past 12 months for ALTIMMUNE INC comes in at -44.18%, a number that bests merely 3.96% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ALT, based on their financial statements, market capitalization, and price volatility, are SYRS, ABUS, CNCE, AUTL, and PIRS.
  • ALT's SEC filings can be seen here. And to visit ALTIMMUNE INC's official web site, go to altimmune.com.

ALT Valuation Summary

  • In comparison to the median Healthcare stock, ALT's price/sales ratio is 5652.83% higher, now standing at 304.9.
  • ALT's EV/EBIT ratio has moved NA NA over the prior 206 months.

Below are key valuation metrics over time for ALT.

Stock Date P/S P/B P/E EV/EBIT
ALT 2022-09-01 304.9 5.4 -10.9 -9.5
ALT 2022-08-31 308.4 5.5 -11.1 -9.7
ALT 2022-08-30 264.5 4.7 -9.5 -8.1
ALT 2022-08-29 271.0 4.8 -9.7 -8.3
ALT 2022-08-26 257.7 4.6 -9.2 -7.8
ALT 2022-08-25 262.4 4.7 -9.4 -8.0

ALT Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -119.43%.
  • Its 2 year net income to common stockholders growth rate is now at -355.69%.
  • Its 3 year net cashflow from operations growth rate is now at -808.9%.
Over the past 15 months, ALT's revenue has gone down $3,334,632.

The table below shows ALT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 3.475217 -69.97215 -96.93701
2022-03-31 3.60484 -72.19478 -101.6567
2021-12-31 4.410356 -78.23794 -97.09082
2021-09-30 3.445404 -69.68439 -83.82328
2021-06-30 6.225836 -61.41412 -68.08273
2021-03-31 6.809849 -49.65839 -60.02294

ALT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALT has a Quality Grade of D, ranking ahead of 13.22% of graded US stocks.
  • ALT's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • OPTN, ENTA, and ELTP are the stocks whose asset turnover ratios are most correlated with ALT.

The table below shows ALT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.025 1 -0.839
2021-03-31 0.032 1 -0.867
2020-12-31 0.052 1 -0.992
2020-09-30 0.058 1 -1.332
2020-06-30 0.062 1 -1.567
2020-03-31 0.089 1 -1.191

ALT Price Target

For more insight on analysts targets of ALT, see our ALT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.86 Average Broker Recommendation 1.36 (Strong Buy)

ALT Stock Price Chart Interactive Chart >

Price chart for ALT

ALT Price/Volume Stats

Current price $20.03 52-week high $23.49
Prev. close $20.24 52-week low $3.83
Day low $19.95 Volume 138,446
Day high $20.61 Avg. volume 1,182,176
50-day MA $14.77 Dividend yield N/A
200-day MA $9.10 Market Cap 981.97M

Altimmune, Inc. (ALT) Company Bio


Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.


ALT Latest News Stream


Event/Time News Detail
Loading, please wait...

ALT Latest Social Stream


Loading social stream, please wait...

View Full ALT Social Stream

Latest ALT News From Around the Web

Below are the latest news stories about ALTIMMUNE INC that investors may wish to consider to help them evaluate ALT as an investment opportunity.

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Altimmune (ALT - Research Report), with a price target of $26.00. The company's shares closed yesterday at $18.94.Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Agenus. According to TipRanks, Mamtani has an average return of -23.6% and a 24.29% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.17, representing a 64.57% upside. In a report released on August 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.

Jason Carr on TipRanks | August 31, 2022

Altimmune (ALT) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune (ALT - Research Report) today and set a price target of $50.00. The company's shares closed yesterday at $17.66.According to TipRanks, Trucchio is an analyst with an average return of -7.6% and a 41.39% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Precision BioSciences, and Immunocore Holdings.Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.40, representing a 77.80% upside. In a report released on August 15, Guggenheim also maintained a Buy rating on the stock with a $31.00 price target.

Christine Brown on TipRanks | August 17, 2022

JMP Securities Remains a Buy on Altimmune (ALT)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Altimmune (ALT - Research Report), with a price target of $25.00. The company's shares opened today at $12.75.According to TipRanks, Wolleben is an analyst with an average return of -1.3% and a 44.63% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Clearside Biomedical.Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $21.60, representing a 69.41% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.

Brian Anderson on TipRanks | August 11, 2022

Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update

Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected mid-September 2022GAITHERSBURG, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2022, and provided a business update. “We continue to advance the development of pemvidutide, our GLP-1/glucagon dual receptor agonist, and look

Yahoo | August 11, 2022

Altimmune (ALT) Gets a Buy Rating from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $21.00. The company's shares closed last Wednesday at $11.51. According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -28.1% and a 21.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $21.00, which is a 66.1% upside from current levels.

Howard Kim on TipRanks | August 4, 2022

Read More 'ALT' Stories Here

ALT Price Returns

1-mo 62.45%
3-mo 134.27%
6-mo 187.79%
1-year 21.32%
3-year 840.38%
5-year -72.41%
YTD 118.67%
2021 -18.79%
2020 496.83%
2019 -8.25%
2018 -96.55%
2017 -48.19%

Continue Researching ALT

Here are a few links from around the web to help you further your research on Altimmune Inc's stock as an investment opportunity:

Altimmune Inc (ALT) Stock Price | Nasdaq
Altimmune Inc (ALT) Stock Quote, History and News - Yahoo Finance
Altimmune Inc (ALT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.702 seconds.